A new phase 3 trial shows significantly prolonged overall survival for patients with AML
Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia in remission after chemotherapy in the QUAZAR AML-001 trial of oral AZACITIDINE.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
